← Back to Search

Unknown

NO-13065 for Obesity

Phase 1
Waitlist Available
Research Sponsored by Otsuka Pharmaceutical Factory, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 35 days
Awards & highlights

Study Summary

This study is evaluating whether a drug may have the potential to help individuals with obesity.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 35 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 35 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The number and severity of treatment emergent adverse events (TEAEs)
Secondary outcome measures
Apparent first-order terminal elimination half-life (t ½)
Area under the plasma concentration-time curve (AUC)
Correlation between QTc and NO-13065 plasma concentrations
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NO-13065, oral tabletExperimental Treatment1 Intervention
Group II: Placebo matched to NO-13065, oral tabletPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NO-13065
2021
Completed Phase 1
~90

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

CelerionIndustry Sponsor
81 Previous Clinical Trials
7,730 Total Patients Enrolled
Otsuka Pharmaceutical Factory, Inc.Lead Sponsor
Koushi IwataStudy ChairOtsuka Pharmaceutical Factory, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects
2021. "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04838639.
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top